Rearrangements involving the IGH gene have been identified in numerous different tumour types. There are a number of stereotypical translocations involved in each of the diseases and more are being described regularly.
The t(8;14)(q24;q32), involving IGH and the MYC gene, is the most common rearrangement in Burkitt's lymphoma and occurs in around 85% of cases1. IGH rearrangements have also been noted in 50% of non-Hodgkin B-cell lymphomas (NHLs) and have been correlated to clinically relevant subgroups2. One study showed that the t(14;18)(q32;q21) (IGH-BCL2) was found in 88.1% of follicular lymphomas and the t(11;14)(q13;q32) (IGH-CCND1) in 85.7% of mantle cell lymphomas2. IGH rearrangements were also identified in 52.5% of diffuse large B-cell lymphomas (DLBCL)1.
IGH is commonly rearranged in lymphomas and has many different translocation partners. We have, therefore, designed a split probe set for IGH, which allows the detection of rearrangements of the IGH gene, regardless of partner gene or chromosome involved.
1. Hoffman, Ronald (2009). Hematology : basic principles and practice (5th ed. ed.). Philadelphia, PA: Churchill Livingstone/Elsevier. pp. 1304–1305
2. Bernicot et al., Cytogenet Genome Res. 2007;118(2-4):345-52
- Area of Interest*
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples, or formalin-fixed paraffin-embedded (FFPE) tissues.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.